Best US Biotech Stocks to Invest In
AI-curated Biotech stock ideas for the US market, each with a buy signal, future-value target and a short thesis. Refreshed every weekday from end-of-day data.
21 picks · prices as of close 2026-10-27
Moderna, Inc.
Analyst upgrade, breakout momentum, and strategy reset support a rebound if execution stabilizes.
▸William Blair upgrade and strong momentum after new 52-week high.
Krystal Biotech, Inc.
Commercial momentum, bullish analyst revision, and multiple 2026 pipeline readouts support further upside.
▸Jefferies raised target after stronger U.S. demand and pipeline progress.
Biogen Inc.
Upgraded on approaching pipeline readouts and a supportive institutional ownership base.
▸Truist and Wolfe upgrades ahead of major data catalysts.
AbCellera Biologics Inc.
Insider interest and a near-term Phase 2 efficacy readout create a favorable catalyst setup.
▸Insider buying and Q3 clinical data catalyst.
Alpha Cognition Inc. Common Stock
Sales ramp plus insider accumulation make this a high-upside, event-driven biotech name.
▸Insider buying and Zunveyl commercial ramp.
Immunovant, Inc.
Recent share offering attracted insider buying, improving risk-reward into upcoming data.
▸Post-offering insider buying supports the stock.
Kymera Therapeutics, Inc.
Insider buying and pipeline depth support upside if clinical execution stays on track.
▸Insider buying after financing and pipeline progress.
Wave Life Sciences, Inc.
Recent insider buying and multiple RNA catalysts position shares for re-rating.
▸Insider buying after share offering and catalyst pipeline.
Tandem Diabetes Care, Inc.
New coverage and improving sentiment can support a rebound if execution stabilizes.
▸Fresh analyst initiation and improving momentum.
Beta Bionics, Inc.
Initiation coverage and category momentum make this an emerging commercial growth story.
▸New analyst initiation supports early momentum.
Aurinia Pharmaceuticals Inc.
Biotech breakout sentiment and accumulation dynamics favor a continued move higher.
▸Included in biotech breakout list with bullish insider sentiment.
Q32 Bio Inc.
Speculative upside remains compelling if clinical results validate the platform.
▸Potential catalyst exists, but confirmation is still limited.
Atrium Therapeutics, Inc.
Strong platform story and event-driven biotech appetite support constructive upside.
▸Momentum and pipeline catalyst potential remain favorable.
Alnylam Pharmaceuticals, Inc.
Established RNA platform, strong momentum, and visible pipeline catalysts support quality growth.
▸Positive momentum and durable platform execution.
Vertex Pharmaceuticals Incorporated
High-quality earnings base and multiple pipeline shots provide steady upside potential.
▸Strong momentum and recurring catalyst visibility.
Sarepta Therapeutics, Inc.
Controversial but liquid name with major catalyst optionality and high beta upside.
▸Large catalyst potential, but risk profile remains elevated.
Genmab A/S
Strong oncology franchise and pipeline visibility offer attractive forward value.
▸Steady pipeline execution and resilient momentum.
Incyte Corporation
Valuation looks reasonable for a cash-generative biotech with near-term pipeline catalysts.
▸Defensive biotech cash flow with catalysts ahead.
Regeneron Pharmaceuticals, Inc.
Quality large-cap biotech with strong fundamentals and visible pipeline support.
▸Institutional support and durable earnings momentum.
BeOne Medicines AG
Global oncology growth and improving sentiment make this a liquid biotech standout.
▸Positive momentum and broad oncology catalysts.
BioMarin Pharmaceutical Inc.
Steady commercial execution and improving sentiment support moderate upside.
▸Stable momentum and pipeline optionality.